AbbVie Wins FDA Approval for Juvmo Treatment for Parkinson's Disease

AbbVie received FDA approval for Juvmo (tavapadon), a new once-daily treatment for Parkinson's disease, expected in October. Additionally, the company announced an AI-driven collaboration with Iambic for small-molecule discovery across multiple therapeutic areas.